Adagio Medical Holdings, Inc
1.1900-0.08 (-6.3%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · ADGM · USD
Key Stats
Market Cap
29.96MP/E (TTM)
-Basic EPS (TTM)
-2.89Dividend Yield
0%Recent Filings
8-K
Adagio closes $19M financing
Adagio Medical Holdings closed its private placement on October 20, 2025, raising $19 million upfront from existing and new institutional investors. The funds will support FDA submission for the vCLAS ULTC System based on the completed FULCRUM-VT study, advance next-generation catheter development, and extend cash runway into key milestones. This bolsters execution amid positive clinical feedback from over 350 patients treated. Yet risks persist in regulatory approvals.
8-K
Strong VT ablation results
Adagio Medical unveiled preliminary acute results from its FULCRUM-VT study on October 10, 2025, showing 97.4% acute success in eliminating targeted ventricular tachycardias using ULTC technology across 207 patients with ischemic and non-ischemic cardiomyopathies. Procedure times averaged 206 minutes, with a 2.5% major adverse event rate, including one device-related death. This bolsters the case for FDA approval. Six-month data awaits in 2026.
8-K
CFO appointment expands leadership
Adagio Medical Holdings appointed Deborah Kaster, its Chief Business Officer, as Chief Financial Officer effective September 5, 2025, succeeding interim CFO Daniel George. Kaster, with over 25 years in medical device finance, will oversee financial operations alongside business development and strategy, backed by a $366,000 base salary and up to 40% bonus. This dual role sharpens alignment between strategy and finances. Yet risks persist in executing growth amid regulatory hurdles.
10-Q
Q2 FY2025 results
Adagio Medical Holdings posted no revenue in Q2 FY2025 ended June 30, 2025, down 100% y/y from $0.3M in the prior-year predecessor quarter, as the company paused European commercial activity to prioritize U.S. regulatory progress. Operating loss narrowed to $4.7M from $6.7M y/y, driven by 31% lower R&D spend on clinical trials and a 29% cut in SG&A from headcount reductions under its February 2025 prioritization initiative. Net loss improved to $3.9M from $5.7M y/y, aided by a $1.4M gain on convertible notes fair value adjustment, while diluted EPS of $(0.35) reflects 15.4M shares with no anti-dilution effects. Cash burned $11.9M in H1 to $8.2M, with $17.0M in convertible notes due in 3.75 years at 13%; free cash flow not disclosed in the 10-Q. Yet cash lasts only to Q4 2025. Regulatory hurdles could delay FDA approval.
8-K
Q2 loss narrows; study advances
Adagio Medical Holdings reported Q2 2025 net loss of $3.9 million, down from $5.7 million year-over-year, with cash at $8.2 million after trimming R&D and SG&A expenses via operational streamlining. The company hit over 85% enrollment in its FULCRUM-VT pivotal study for the vCLAS Cryoablation System, targeting FDA approval for VT treatment by late 2025. Pulsed Field Cryoablation data reinforced safety. Cash burn slowed, yet runway remains tight.
ADAG
Adagene Inc.
1.84+0.04
AEMD
Aethlon Medical, Inc.
5.75+0.32
BDMD
Baird Medical Investment Holdin
1.44+0.02
ICCM
IceCure Medical Ltd.
0.75-0.02
IRTC
iRhythm Technologies, Inc.
185.29+2.62
MODD
Modular Medical, Inc.
0.52-0.01
NVNO
enVVeno Medical Corporation
0.72+0.00
ODYY
Odyssey Health Inc.
0.08+0.00
PMI
Picard Medical, Inc.
3.28-0.77
SENS
Senseonics Holdings, Inc.
7.25+0.05